Cell and Gene Outsourcing

31. The Immune System's Secret Language: Unlocking Cellular Communication 10/15/2025

    The rising rate of autoimmune conditions requires better ways to monitor cellular activity. See how profiling immune cells by their DNA signatures enables real-time therapeutic insight and prediction.

32. Prospecting Biospecimen Collections To Power Precision Medicine 10/15/2025

    High-quality biospecimens are the foundation of precision medicine success. Learn the five crucial steps—from planning to compliance—for a prospective biospecimen collection that is scientifically robust and accelerates your research.

33. Starting A New Study? This One's For You 10/15/2025

    Choosing the right vendor at trial launch impacts costs, timelines, data integrity, and patient experience — yet vendor selection in clinical research remains fundamentally broken today.

34. September 2025 — CDMO Opportunities And Threats Report 10/14/2025

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

35. Know Your Product, Know Your Path: A Primer On Advanced Therapy Development 10/9/2025

    To prevent path-to-market setbacks, it is critical to develop a Chemistry, Manufacturing, and Controls strategy that proactively identifies scientific and compliance gaps, as well as mitigates risk.

36. Purpose-Built For ADC Development 10/9/2025

    Antibody-drug conjugates (ADCs) are transforming cancer care by combining precision antibody targeting with potent payloads to improve patient outcomes.

37. Deliver Potent Cell Therapies Faster, More Reliably And Enhance Cell Properties 10/8/2025

    Accelerate the next generation of cell-based therapies with innovative technologies that streamline manufacturing, enhance scalability, and expand patient access worldwide.

38. Translating Groundbreaking Research Into Life-Changing Therapies 10/8/2025

    Our flexible partnership models empower you to scale efficiently and confidently — whether advancing a single molecule or managing a complex portfolio of therapeutic candidates.

39. Managing Cell Therapy Investigational New Drug (IND) Timeline Risks 10/7/2025

    Managing timelines to IND is the top challenge in cell therapy, impacting funding, patent value, and patient access amid competitive, capital-constrained development environments.

40. Key CMC Step For Cell Therapy IND Success 10/7/2025

    Ensure cell therapy products are consistently manufactured with safety, quality, and potency, supporting regulatory approval and successful clinical development.